αvβ8-Integrin is a potent modulator of the immune system and furthermore – like αvβ6-integrin – an activator of transforming growth factor β (TGFβ). As such, the expression level of αvβ8-Integrin in tissues is connected to a multitude of biological and pathological mechanisms involving TGFβ, including, but not limited to, cancer progression and metastasis.
[1]TRIMT’s αvβ8-Integrin targeted positron emission tomography (PET) tracer 68Ga-Triveoctin was developed on the basis of a unique, highly selective octapeptide (see Image).[2] 68Ga-Triveoctin is the first clinically relevant αvβ8-Integrin specific agent of this type.[3] Potential applications include stratification of patients for αvβ8-Integrin-targeted therapies by non-invasive PET imaging.
[1]
Takasaka N, et al., JCI Insight 2018;3:e122591. [2]
Reichart F, et al., J. Med. Chem. 2019;6:2024.[3]
Quigley NG, et al., EJNMMI Res. 2020;10:133.